Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Drug Policy / Regulatory

Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis

Fineline Cube Jul 17, 2023

Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...

Company Deals

Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical

Fineline Cube Jul 14, 2023

UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...

Company

Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results

Fineline Cube Jul 14, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...

Company Deals

InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination

Fineline Cube Jul 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...

Company Drug

GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China

Fineline Cube Jul 14, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...

Company Medical Device

Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA

Fineline Cube Jul 14, 2023

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...

Company Deals

GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs

Fineline Cube Jul 14, 2023

China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...

Company Drug

BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA

Fineline Cube Jul 13, 2023

China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer

Fineline Cube Jul 13, 2023

Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...

Company Policy / Regulatory

US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage

Fineline Cube Jul 13, 2023

The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...

Company Drug

Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA

Fineline Cube Jul 13, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Deals

DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong

Fineline Cube Jul 13, 2023

China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth...

Company Deals

LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial

Fineline Cube Jul 13, 2023

Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...

Company Deals

Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech

Fineline Cube Jul 13, 2023

Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a...

Company Deals

Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential

Fineline Cube Jul 13, 2023

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...

Company Drug

Kedrion Biopharma Achieves First Product Approval in China for Human Albumin

Fineline Cube Jul 13, 2023

Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL),...

Company Drug

GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE

Fineline Cube Jul 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell...

Company Deals

Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab

Fineline Cube Jul 12, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...

Company Legal / IP

Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jul 12, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...

Company Deals Medical Device

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Fineline Cube Jul 12, 2023

OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...

Posts pagination

1 … 548 549 550 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.